Modern biopharma development requires more than just a LIMS and spreadsheets. Learn why in this article by Alberto Pascual, IDBS, featuring Accenture and published in Lab Manager.
Compared to most other industries, life science and biopharmaceutical companies have been slow to embrace digital technologies. Why?
As the biopharmaceutical industry begins to embrace advanced data collection and analysis tools, it finds itself facing a challenging question: How can drug manufacturers best harness all that data to improve capacity, reduce bottlenecks and cut costs?
Wondering if an ELN can be used as a LIMS? Hear from IDBS and other experts in this interesting piece published in Lab Manager.
Throughout the past few years, there’s been a clear trend in the makeup of approvals, with biologics representing a growing percentage. But even within biologics, newer technologies like mRNA, cell, and gene therapies are gaining ground. The approvals are not one-off events, but evidence of an exciting long-term trend. Learn more from Christian Marcazzo, General Manager at IDBS, in his article published in Drug Development & Discovery.
Around this time last year, the first COVID-19 vaccines were authorized for emergency use. A year before that, COVID-19 had not yet been declared a pandemic. It goes to show how much can change in this industry, as well as how important this sector is. Hear predictions from experts, including Alberto Pascual, in this article, published in Drug Discovery World.
When you factor in the unpredictability and complexity of therapies like biologics, the time impacts of poorly managed data are on the order of 6–18 months. Find out more on why legacy data management systems can’t support the directions…
The biopharma industry may have been slow to embrace digital technologies, but it’s catching up fast. The innovation we’re seeing in predictive modeling and machine learning could truly revolutionize the entire lifecycle of drug discovery and development. Take a…
Life sciences companies are using digital twins for everything from drug discovery to manufacturing. Hear from a panel of experts at MedCity News’ INVEST Digital Health conference, moderated by Accenture, where companies, including IDBS, discuss how this capacity to…
The licensing and integration of Scitara DLX technology will offer IDBS users plug-and-play connectivity to any instrument or application in regulated and non-regulated laboratories
